Fig. 5

Patient-derived xenograft (PDX) model suggested sensitivity to cisplatin was restored. Hematoxylin and eosin (H&E) staining of patient tumor. b Hematoxylin and eosin (H&E) staining of PDX model. c Gross view of PDX tumor at the end of the experiment. d Tumor weight calculated at the end of the experiment. Average weight of vehicle, cisplatin, docetaxel, irinotecan, 5-Fu, mitomycin, pemetrexed and pazopanib groups were 1.13 ± 0.47 g, 0.23 ± 0.07 g, 0.43 ± 0.23 g, 0.43 ± 0.29 g, 0.69 ± 0.16 g, 0.68 ± 0.29 g, 0.48 ± 0.19 g and 0.68 ± 0.35 g.*P < 0.05. e Tumor growth curves of all groups. Treatment groups (TGI > 50%) excluding pazopanib group show statistically significant tumor growth inhibition compared to vehicle group. TGI > 50% is considered meaningful